Rami Manochakian, MD, FASCO, of Mayo Clinic Florida, summarizes an educational session at ASCO that reviewed the state of the field of small cell lung cancer (SCLC). After decades of limited treatment progress, advances are being seen in immunotherapies, radiation therapy, antibody-drug conjugates, and radionuclide therapies.
Jason R. Westin, MD, FASCO, of The University of Texas MD Anderson Cancer Center, provides an update on the safety and efficacy data from the phase III SUNMO trial, which compared mosunetuzumab and polatuzumab vedotin vs rituximab, gemcitabine, and oxaliplatin in patients with relapsed or refractory large B-cell lymphoma (LBCL) (Abstract 7007).
Erika P. Hamilton, MD, FASCO, of Sarah Cannon Research Institute, talks about a comparison of the efficacy and safety of tucatinib vs placebo combined with trastuzumab and pertuzumab as maintenance therapy for HER2-positive metastatic breast cancer by stratified subgroups (Abstract 1005).
Ramez N. Eskander, MD, of UC San Diego Moores Cancer Center, presents an updated overall survival analysis and examination of subsequent therapy in patients with endometrial cancer treated with pembrolizumab plus carboplatin/paclitaxel as compared to carboplatin/paclitaxel plus placebo in the NRG-GY018 trial (Abstract 5502).
Ghassan K. Abou-Alfa, MD, PhD, FASCO, of Memorial Sloan Kettering Cancer Center and Weill Medical College at Cornell University, presents efficacy and safety data from the randomized phase III EMERALD-3 trial, which evaluated tremelimumab plus durvalumab with or without lenvatinib combined with transarterial chemoembolization in patients with unresectable embolization-eligible hepatocellular carcinoma (LBA4000).
Jame Abraham, MD, FACP, of Cleveland Clinic, provides an update on the DESTINY-Breast05 trial, which is an ongoing phase III trial investigating postneoadjuvant trastuzumab deruxtecan (T-DXd) as compared with trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with residual invasive disease and node-positive disease at surgery or inoperable disease at diagnosis. Dr. Abraham makes special note of rates of interstitial lung disease seen in the trial and methods of management.
